.
While corneal toxicity secondary to BAK has been shown in prior in vitro and rabbit studies [13] , it is unclear whether these studies accurately replicate ocular surface conditions in patients undergoing treatment with IOPlowering medications preserved with BAK.
Exposure to BAK in some of these studies exceeds that experienced by many patients administering topical medications preserved with BAK.
Recently, a new formulation of bimatoprost 0.01% preserved with 0.02% BAK was approved.
This formulation was designed to maintain the IOP-lowering efficacy of bimatoprost 0.03%
and to provide an improved ocular surface tolerability profile. The present 12-week study was undertaken to examine the ocular surface tolerability of once-daily bimatoprost 0.01%
and latanoprost (both preserved with 0.02% BAK), and travoprost 0.004% (preserved with sofZia) in adult patients with glaucoma or ocular hypertension following a run-in on latanoprost.
there was a statistically significant among-group difference in mean change from baseline in hyperemia (+0.04, bimatoprost; +0.20, travoprost; 0.00, latanoprost; P = 0.018). There were no statistically significant among-group differences in mean corneal staining, mean TBUT, or change from baseline at any visit.
Conclusions: Despite preservative differences, there were no significant differences in objective clinical measures of ocular surface tolerability after 3 months of treatment with bimatoprost (with 0.02% BAK), travoprost (with sofZia), and latanoprost (with 0.02% BAK).
INTRODUCTION
The prostaglandin analogs and prostamides [1, 2] are commonly prescribed first-line medications for glaucoma or ocular hypertension based upon their efficacy in lowering intraocular pressure (IOP), favorable safety and tolerability profiles, and ease of once-daily dosing [3] [4] [5] .
The most frequently reported side effect of these medications, conjunctival hyperemia, is often transient and not associated with inflammation or other negative sequelae [4, 6, 7] .
Prostaglandin analogs (travoprost and latanoprost) and prostamides (bimatoprost) are typically administered from multidose bottles that contain preservatives to ensure sterility.
Benzalkonium chloride (BAK) is the most commonly used preservative in ophthalmic medications as a result of its broad-spectrum bactericidal and bacteriostatic activity at physiological pH [8] [9] [10] [11] . 
Assessments and Outcomes Variables
Study visits were scheduled at consistent times in the morning, at baseline, and weeks 1, 4, and 12.
At each study visit, ocular tolerability and safety assessments were conducted. The primary 
Statistical Analyses
For purpose of analysis, the intent-to-treat (ITT) population included all subjects who were randomized to study medication. The per-protocol (PP) population, a subset of the ITT population, included all subjects who completed 12 weeks of treatment without significant protocol violations.
The safety population included all subjects who were exposed to study medication.
Differences in outcomes among the treatment groups were analyzed using analysis of variance (ANOVA) for the among-group differences, using the ITT population, and last observation carried forward for missing values. In the analysis of conjunctival hyperemia, corneal staining, and TBUT, analyses were performed using the average value of both eyes. If the overall null hypothesis was rejected, pairwise comparisons were made using the two-sample t-test using the PP population. Change from baseline was summarized and analyzed similarly, including the use of a paired t-test for change within a treatment group. In addition, all biomicroscopy changes were summarized for change from baseline at week 12, and categorized as "no change," "decrease ≥0.5," "increase = 0.5,"
"increase >0.5," and "increase ≥1." The analysis was performed using the ITT population and no hypothesis testing was performed.
Safety data were summarized for the safety population. For adverse events, among-group differences were analyzed using a two-tailed
Fisher's exact test. IOP was averaged over both eyes for analysis, and the results at baseline and each follow-up visit were analyzed by ANOVA.
Change from baseline in IOP was summarized at each follow-up visit using analysis of covariance with effects for treatment group and baseline IOP, while within-group change was analyzed using a paired t-test. All observed safety data were analyzed and there was no imputation for missing values. 
RESULTS

Patient Disposition
In total, 164 patients (both ITT and safety population) were randomized to the three treatment groups (Table 1 ) and received study medication; the PP population comprised 150 patients. There were no significant differences among treatment groups in patient demographics or ocular diagnoses at baseline (Table 1) . Treatment history of study population reveals that 68.9% had more than 1 year of treatment, 50.0% had at least 3 years, and 14.0% had more than 10 years of treatment with IOP-lowering medications.
Eleven patients discontinued treatment before week 12 (Table 2) . 
Corneal Staining
There were no significant among-group differences in mean corneal staining at baseline or mean staining at any visit (P ≥ 0.379; Fig. 2 ).
At baseline, the mean (SD) corneal staining score 
Tear Break-up Time
As with corneal staining, there were no statistically significant among-group differences in mean TBUT times at baseline or at any visit.
Mean (SD) TBUT at baseline was 9.7 s (6.14)
in the bimatoprost group, 9. A ≥1-unit increase in conjunctival hyperemia from baseline at week 12 was observed in 2.0%
of the bimatoprost group, 5.9% of the travoprost group, and 3.8% of the latanoprost group (Fig. 4) .
There was either no change or a decrease in corneal staining in 76.5% of the bimatoprost group, 70.6% in the travoprost group, and 67.3% in the latanoprost group. A ≥1-unit increase in corneal staining was observed in 2.0% of the bimatoprost group, 5.9% of the travoprost group, and 3.8% of the latanoprost group (Fig. 4) . There were no statistically significant changes in IOP from baseline following randomization in the latanoprost-treated group at any visit (P ≥ 0.239).
Adverse Events
All three treatments were well tolerated and adverse event incidence rates were comparable among groups (Table 4) Corneal staining and TBUT were not statistically significantly different among the groups at Table 3 Within-group intraocular pressure changes from baseline in the safety population some of these reports, BAK exposure is much greater than that experienced clinically [13] .
Differences in ocular physiology between rabbits and humans, including the presence of a nictitating membrane [15] and differences in blink rate [16, 17] , may account for some of the difference in findings between those preclinical studies and the present study. The present study demonstrates that over 3 months, there was no observable clinical impact on ocular surface tolerability parameters despite differences in preservatives and active agents.
In the present study, all patients were run in on latanoprost monotherapy for 30 days prior to baseline, which may impact tolerability While many preclinical studies using both in vitro and in vivo models have suggested 
